Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
None
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children

This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad population of children. Half of participants will receive the high dose, while the other half will receive the low dose.

stimulation test
somatropin
growth hormone
deficiency
  • 7 views
  • 07 Nov, 2020
  • 1 location
None
Study of Infigratinib in Children With Achondroplasia

This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) …

tyrosine kinase inhibitor
  • 10 views
  • 11 Aug, 2021
  • 15 locations
None
A Study Of Safety Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

Approximately 63 participants will be randomized to one of three doses to receive Recifercept either Low Dose Medium Dose High Dose Participants will will attend the clinic at baseline and at Day 1, 4, 8, 15, 29 & then Month 2, 3 6, 9 & 12. Assessments include safety, blood …

testicular
  • 1 views
  • 22 Oct, 2021
  • 11 locations
None
Albright Hereditary Osteodystrophy: Natural History Growth and Cognitive/Behavioral Assessments

FD003409, IND 67148 or those who meet the criteria of idiopathic short stature or SGA. We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to

  • 110 views
  • 09 Aug, 2021
  • 1 location
None
Efficacy and Safety of rhGH (Jintropin ) in Pediatric Participants With ISS

Phase 1: To evaluate the safety and efficacy of 0.05mg/kg/d of rhGH (Jintropin) in the treatment of children with idiopathic short stature (ISS) in 52 weeks. Phase 2: To evaluate the

stimulation test
somatropin
growth hormone
growth hormone treatment
somatotropin
  • 8 views
  • 22 Jan, 2021
  • 5 locations
None
A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

strategy is used to treat children with ISS (Idiopathic Short Stature). The long-term efficacy and safety of the investigational product are evaluated, which can provide more scientific and reliable

somatotropin
somatropin
growth hormone
igf-i
  • 36 views
  • 21 Jan, 2021
  • 2 locations
None
Vosoritide for Selected Genetic Causes of Short Stature

Short stature can be caused by a number of genetic etiologies, many of which directly affect the growth plate. The FGFR3/CNP pathway is central to growth of the chondrocyte. The study team

vosoritide
growth hormone
shox deficiency
saddan syndrome
hormones levels
  • 8 views
  • 10 May, 2021
  • 1 location
None
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia

Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery

  • 4 views
  • 05 Aug, 2021
  • 3 locations
None
Metabolic Study of Cockayne Syndrome

Cockayne syndrome (CS) is related to defective DNA transcription and/or repair and belongs to the family of Nucleotide Excision Repair. It is an autosomal recessive multisystemic disorder characterized by mental retardation, microcephaly, severe growth failure with lipoatrophia, sensorial impairment, cutaneous photosensitivity, dental decay, enophtalmios. The disease is progressive causing severe …

  • 7 views
  • 20 Sep, 2021
  • 1 location
None
Nutritional Stimulation of Growth in Children With Short Stature

Short stature is a frequent reason for referral to a pediatric endocrinology clinic. Short stature is especially prevalent among those with failure to thrive (whose weight is significantly below

  • 0 views
  • 29 Sep, 2021
  • 1 location